Post-Acute & Long-Term Care Medical Association Issues Commentary: Suzetrigine - A First-in-Class Non-Opioid Analgesic -- Promise With Vigilance
April 07, 2026
April 07, 2026
COLUMBIA, Maryland, April 7 -- Post-Acute and Long-Term Care Medical Association issued the following commentary on April 6, 2026, by Ronald Rosen, geriatrician at Mass General Brigham:
* * *
Suzetrigine: A First-in-Class Non-Opioid Analgesic -- Promise With Vigilance
Suzetrigine (brand name Journavx) is a recently approved, first-in-class, oral, non-opioid analgesic indicated for the treatment of moderate to severe acute pain in adults. Approved by the U.S . . .
* * *
Suzetrigine: A First-in-Class Non-Opioid Analgesic -- Promise With Vigilance
Suzetrigine (brand name Journavx) is a recently approved, first-in-class, oral, non-opioid analgesic indicated for the treatment of moderate to severe acute pain in adults. Approved by the U.S . . .